Overview

Assessing Clinical Trial Outcome of Patients With Relapsed/Refractor Metastatic Osteosarcoma in Adolescents and Adults

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 14 years of age and older who meet the criteria for study enrollment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
MedPacto, Inc.